以护士主导的家庭血尿酸监测用于二级医疗中起始降尿酸治疗的痛风患者的成本效益:一项模型研究
该建模研究从社会视角评估护士主导的家庭血尿酸监测与常规诊疗相比,在二级医疗中起始降尿酸治疗的痛风患者中的成本效益。家庭监测的平均增量净货币效益为91.43欧元(可信区间:-56.49至274.09),两年QALYs从常规诊疗的1.455(CI:1.389至1.517)变为家庭监测的1.459(CI:1.391至1.523)。结论认为护士主导的家庭血尿酸监测可能具有成本效益。
要点
- 家庭监测平均增量净货币效益为91.43欧元(CI:-56.49至274.09)。
- 两年QALYs常规诊疗1.455(CI:1.389至1.517)vs家庭监测1.459(CI:1.391至1.523)。
- 风湿科医生时间减少41分钟(CI:-116至11),护士时间增加52分钟(CI:4至143)。
核心结论
- 该建模研究表明,与常规二级痛风诊疗相比,护士主导的家庭血尿酸监测对起始降尿酸治疗的痛风患者可能具有成本效益。
研究设计与样本
- 成本效益建模研究,从社会视角开展,采用决策树(6个月)和马尔可夫模型(18个月)模拟两年时间跨度。
- 干预为风湿科护士远程支持患者按达标治疗原则调整降尿酸治疗剂量、患者在家进行血尿酸检测;常规诊疗为医院血尿酸监测联合风湿科医生访视,同样遵循达标治疗原则。
- 成本包括药物、提供者时间、实验室/家庭检测费用、交通、生产力损失及痛风发作相关诊疗;健康结局以质量调整生命年(QALYs)衡量。
- 成本效益通过概率敏感性分析判定,支付意愿阈值为每QALY 20,000欧元。
主要发现
- 家庭监测具有成本效益,平均增量净货币效益为91.43欧元(可信区间:-56.49至274.09)。
- 两年QALYs从常规诊疗的1.455(CI:1.389至1.517)变为家庭监测的1.459(CI:1.391至1.523)。
- 风湿科医生时间减少41分钟(CI:-116至11),护士时间增加52分钟(CI:4至143)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the cost-effectiveness of nurse-led home monitoring of serum urate (SU) versus usual care for gout patients starting urate-lowering therapy (ULT) in a secondary care setting. Additionally, the intervention's impact on nurse and rheumatologist time investment was evaluated. METHODS: A cost-effectiveness modeling study was conducted from a societal perspective. Home monitoring involved rheumatology nurses remotely supporting patients with ULT dose adjustments according to treat-to-target (T2T), while patients conducted SU testing at home. Usual care entailed hospital-based SU monitoring with rheumatologist visits also following the T2T approach. A decision tree (6-month period) and a Markov model (18 months) were employed to simulate a two-year timeframe. Costs included medications, provider time, laboratory/home testing expenses, travel, productivity losses, and gout flare-related care. Health outcomes were measured in Quality-Adjusted Life Years (QALYs). Cost-effectiveness was determined via probabilistic sensitivity analyses using a €20,000 per QALY willingness-to-pay threshold. RESULTS: Home monitoring proved cost-effective, yielding a mean incremental net monetary benefit (iNMB) of €91.43 (credible interval (CI): -56.49 to 274.09). QALYs changed marginally from 1.455 (CI: 1.389 to 1.517) under usual care to 1.459 (CI: 1.391 to 1.523) with home monitoring over two years. Rheumatologist time was reduced by 41 min (CI: -116 to 11), though nurses spent an additional 52 min (CI: 4 to 143). CONCLUSION: This modeling study demonstrates that nurse-led home monitoring of serum urate levels in gout patients starting ULT is likely to be cost-effective compared to usual secondary gout care.
引用
- van der Ven J, Flendrie M, van Dijck F, et al. Cost-effectiveness of nurse-led home monitoring of serum urate for gout patients starting with urate-lowering therapy in secondary care: a modeling study. Semin Arthritis Rheum. 2025. PMID: 40763440. doi:10.1016/j.semarthrit.2025.152782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。